Sail Biomedicines has entered a strategic collaboration with Johnson & Johnson to develop in vivo chimeric antigen receptor T-cell therapies for immune-mediated diseases, pairing Sail’s RNA and targeted nanoparticle technology with Johnson & Johnson’s development, manufacturing and commercial capabilities. The structure includes $785 million in initial payments, including a $465 million equity investment, as well as up to $140 million linked to development milestones and an exclusive Johnson & Johnson option to acquire Sail for another $2.58 billion.
The transaction is unusually large for a platform whose lead therapeutic work remains preclinical. It signals that Johnson & Johnson sees in vivo CAR-T not simply as another experimental cell therapy, but as a potential way to convert the biological power of CAR-T treatment into a more scalable pharmaceutical product that could eventually reach patients outside the limited network of specialist cell therapy centres.
That strategic endorsement should not be confused with clinical validation. Sail has reported encouraging findings from animal models and laboratory studies, but it has not disclosed human clinical results for its lead in vivo CAR-T candidate. The central test will be whether the company can reproduce selective T-cell programming, controlled CAR expression and deep immune-cell depletion in patients without introducing unacceptable off-target activity or immune toxicity.
What are the key takeaways from the Sail Biomedicines and Johnson & Johnson collaboration?
Johnson & Johnson is gaining access to Sail’s Endless RNA constructs, targeted nanoparticle delivery technology and artificial intelligence-supported product design capabilities. The partners intend to advance Sail’s lead programme in autoimmune and other immune-mediated diseases while using the platform to pursue additional targets over time. Janssen Biotech is the Johnson & Johnson company entering the collaboration, while Johnson & Johnson Innovation is making the equity investment.
The financial structure gives Johnson & Johnson several levels of participation. It becomes a major investor, collaborates on development and retains the right to buy the company if the platform achieves sufficient scientific and strategic progress. The headline value should nevertheless be interpreted carefully. The $140 million in development payments depends on specified milestones, while the $2.58 billion acquisition payment would arise only if Johnson & Johnson exercises its option.
Adding the disclosed components produces potential consideration exceeding $3.5 billion, but that is not money Sail has already received or is guaranteed to receive. The staged arrangement instead allows Johnson & Johnson to secure strategic control over a promising platform while preserving the ability to reassess its value as preclinical, regulatory and clinical evidence develops.
Why is Johnson & Johnson committing substantial capital before Sail reports human data?
The attraction lies in what in vivo CAR-T could remove from the traditional cell therapy process. Approved autologous CAR-T products generally require patient-cell collection, specialised ex vivo engineering, expansion, quality testing, transportation and reinfusion. Patients may also need lymphodepleting chemotherapy before treatment. These steps create long lead times, high manufacturing costs and dependence on qualified treatment centres.
Sail is attempting to replace that patient-specific manufacturing chain with an injectable RNA and nanoparticle medicine that programmes a patient’s T cells inside the body. Its platform is designed to deliver RNA instructions selectively to CD4 and CD8 T cells, causing them to express a chimeric antigen receptor for a controlled period. The engineered cells would then attack the disease-relevant immune-cell population without requiring permanent genetic integration.
For Johnson & Johnson, successful in vivo programming could create a product that behaves commercially more like a repeatably manufactured medicine than a bespoke cellular procedure. A single manufactured batch could theoretically treat multiple patients, although the companies have not yet demonstrated that proposition through commercial-scale production or human treatment.
The option-based structure reflects this combination of potential and uncertainty. Johnson & Johnson is paying heavily for access and strategic priority, but it is postponing the final acquisition decision until the development programme produces additional information. That reduces the risk of losing the platform to a competitor while avoiding an immediate full-company takeover based solely on preclinical data.
How does Sail’s eRNA and targeted nanoparticle platform aim to create CAR-T cells inside the body?
Sail’s platform combines circular RNA technology, described by the company as Endless RNA, with nanoparticles engineered to deliver that RNA to selected immune cells. The RNA carries instructions for a chimeric antigen receptor, while the nanoparticle is intended to determine which cells receive those instructions.
Sail has designed its approach to generate transient CAR expression rather than permanent genomic modification. In principle, that could provide a therapeutic window long enough to deplete pathogenic immune cells while allowing CAR activity to diminish afterwards. The temporary expression profile may be particularly relevant in autoimmune diseases, where permanent or extremely prolonged immune-cell depletion might create unnecessary infection and immunodeficiency risks.
The company previously identified SAIL-0804 as its first in vivo CAR-T development candidate. Sail said the investigational candidate uses an anti-CD19 CAR encoded by circular RNA and delivered through targeted lipid nanoparticles. It was designed for intravenous administration without cell harvesting or a conditioning regimen, although those proposed advantages remain to be confirmed in clinical trials.
Johnson & Johnson brings experience in both immunology and commercial CAR-T therapy, but Sail’s modality introduces different development requirements. The final medicine would be an RNA and nanoparticle product that generates CAR-T cells after administration, meaning regulators will need evidence covering the manufactured delivery system and the cellular activity produced inside each patient.
What do Sail’s preclinical findings establish, and what remains scientifically unproven?
At the American Society of Gene and Cell Therapy meeting in 2025, Sail reported that SAIL-0804 produced broad B-cell depletion in humanised mouse models, including in blood, spleen, lymph nodes and bone marrow. The company also reported T-cell transfection rates of 50% to 80% across rodent, non-human primate and laboratory human-cell systems, with CAR expression continuing for several days after dosing.
Sail further reported that B cells returning after depletion displayed predominantly immature characteristics, which it interpreted as evidence supporting an immune-reset hypothesis. During 2026, the company said additional presentations would include non-human primate findings and data supporting deep B-cell depletion across blood and lymphoid tissues.
These findings support continued development but do not demonstrate clinical efficacy, durable remission or an acceptable human safety profile. Human biology may alter nanoparticle distribution, T-cell uptake, CAR expression, immune activation and clearance. The dose needed to programme enough T cells could also affect the risk of systemic inflammation or delivery to unintended cell populations.
The ability to generate both CD4 and CD8 CAR-T cells may strengthen biological activity, but it also makes control of dose and pharmacology important. Unlike an ex vivo product, where the number and characteristics of infused cells can be measured before administration, in vivo CAR-T developers must predict how many cells will be programmed after the delivery system enters a patient.
Regulators are therefore likely to focus on biodistribution, cell selectivity, off-target transfection, cytokine release, neurological effects, immune responses against the delivery system and the duration of CAR expression. Transient, non-integrating RNA can reduce concerns associated with permanent insertion into the genome, but it does not automatically remove the established inflammatory and neurological risks associated with activated CAR-T cells.
Why have autoimmune diseases become an important target for CAR-T immune-reset strategies?
The clinical rationale comes from early studies of conventional CD19-directed CAR-T therapies in severe autoimmune diseases. A 2024 New England Journal of Medicine case series involving 15 patients with systemic lupus erythematosus, systemic sclerosis or idiopathic inflammatory myositis reported results supporting the feasibility of the approach, while later prospective research has continued to examine whether deep B-cell depletion can produce sustained drug-free remission.
These studies have raised interest in the idea of an immune reset. Rather than repeatedly suppressing inflammatory pathways, CAR-T therapy may eliminate disease-driving B-cell populations deeply enough to allow a healthier B-cell compartment to return. The strongest evidence, however, remains concentrated in small numbers of patients with severe and treatment-refractory disease.
That distinction is essential for Sail’s commercial argument. Positive experience with ex vivo CAR-T supports the biological target, particularly CD19-mediated B-cell depletion, but it does not prove that an RNA nanoparticle can generate the same activity or clinical durability. Sail must show that transient CAR expression is sufficiently long and potent to remove pathogenic cells from blood, bone marrow and tissues while remaining controllable.
Patient selection will also matter. Autoimmune diseases include biologically diverse conditions, and B cells do not play the same role in every patient or at every disease stage. Development programmes will need clear inclusion criteria, disease-specific endpoints and evidence that any improvement persists after CAR-T cells and depleted B cells are no longer detectable.
Can Johnson & Johnson turn Sail’s platform into a scalable pharmaceutical product?
The collaboration gives Sail access to capabilities that become increasingly important after candidate selection. Johnson & Johnson can support clinical development, regulatory planning, manufacturing process design, global trial execution and eventual commercial access. Its immunology organisation can also help identify the diseases and patient populations where deep B-cell depletion offers the strongest therapeutic rationale.
Manufacturing remains one of the most consequential uncertainties. Sail must produce consistent RNA constructs and targeted nanoparticles with tightly controlled size, composition, potency, purity and targeting characteristics. Small manufacturing changes could alter where the particles travel, which cells they enter and how much CAR protein is expressed.
The companies will also need assays capable of connecting the administered dose to the number, phenotype and persistence of CAR-positive T cells generated in patients. That relationship may vary according to prior immunosuppressive therapy, baseline lymphocyte counts, disease activity and individual immune status.
Even if the platform eliminates patient-specific manufacturing, it may not immediately eliminate specialist clinical supervision. Initial trials are likely to require close monitoring for cytokine release syndrome, neurological symptoms, infections, changes in blood-cell populations and unexpected tissue effects. Wider outpatient or community use would depend on a safety profile strong enough to justify moving treatment away from experienced cellular therapy centres.
What does the collaboration mean for Johnson & Johnson investors and near-term earnings?
Johnson & Johnson said that exercising the option and meeting specified deal conditions would reduce adjusted earnings per share by approximately $0.18 in 2026 and $1.28 in 2027. The company subsequently lowered its 2026 adjusted earnings forecast to between $10.96 and $11.11 per share from an earlier range of $11.60 to $11.75, reflecting the combined impact of the Sail agreement and its acquisition of Firefly Bio. Revenue expectations remained unchanged.
Johnson & Johnson shares closed July 29 at $265.53, down about 0.45% during regular trading, before declining around 1.6% in extended trading following the guidance revision. The reaction suggests investors were weighing the longer-term pipeline value of the transactions against their more immediate earnings cost.
For a company of Johnson & Johnson’s scale, Sail is not a balance-sheet-defining transaction. It is more meaningful as an indication of research priorities. The company is prepared to accept near-term dilution to gain an early position in a modality that could eventually challenge both chronic immunology medicines and the existing infrastructure-heavy CAR-T model.
The market is unlikely to assign substantial product value until Sail enters clinical development. Near-term sentiment will therefore depend more on regulatory progress, candidate selection and first-in-human data than on the acquisition option’s headline value.
Which milestones will determine whether Johnson & Johnson exercises its Sail acquisition option?
The companies did not announce a confirmed first-in-human dosing date. The most important next step will be completion of the non-clinical pharmacology, toxicology and manufacturing work required to support an Investigational New Drug application or an equivalent regulatory submission.
Early clinical testing must determine whether Sail can selectively programme enough T cells at a tolerable dose, whether the resulting CAR expression is predictable and whether B-cell depletion reaches the tissues believed to sustain autoimmune disease. Investigators will also examine how quickly B cells recover, whether disease activity returns and whether protective immune function is preserved.
Evidence supporting administration without lymphodepletion would materially strengthen Sail’s differentiation, but that claim remains preclinical. The same applies to outpatient delivery and repeat dosing. These characteristics must be demonstrated rather than inferred from the temporary nature of the RNA payload.
Johnson & Johnson’s acquisition option will become strategically valuable only if Sail can convert an attractive engineering concept into reproducible human pharmacology. The collaboration provides financial resources, development infrastructure and commercial reach. It does not remove the fundamental challenge facing every in vivo CAR-T developer: generating powerful cellular activity inside a patient while retaining enough control to make that activity safe, predictable and manufacturable at pharmaceutical scale.
